7,8-dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo<2,1-i>purin-5(4H)-one | 149744-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 7,8-dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo<2,1-i>purin-5(4H)-one
• 英文别名: 8-ethyl-4-propyl-2-(3-tricyclo[3.3.1.03,7]nonanyl)-7,8-dihydro-1H-imidazo[2,1-f]purin-5-one
• CAS: 149744-78-5
• 化学式: C₂₁H₂₉N₅O
• 分子量: 367.494
• InChiKey: KWTCMZRWMFFRBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-(methylthio)-8-(3-noradamantyl)-3-propyl-7H-purin-2(3H)-one 在 氯化亚砜 作用下， 以 二甲基亚砜 为溶剂， 生成 7,8-dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo<2,1-i>purin-5(4H)-one
  参考文献：
  名称：

  7,8-二氢-8-乙基-2-（3-金刚烷基）-4-丙基-1H-咪唑并[2,1-i]嘌呤-5（4H）-一个：有效的水溶性腺苷A1拮抗剂。

  摘要：

  DOI：

  10.1021/jm00097a016

文献信息

• Methods of treating pulmonary disease
  申请人：——

  公开号：US20040259889A1

  公开（公告）日：2004-12-23

  Methods useful for reducing pulmonary vasoconstriction or improving pulmonary hemodynamics in a patient are disclosed. More particularly, this invention relates to administering A 1 adenosine receptor antagonists to reduce pulmonary vasoconstriction and improve pulmonary hemodynamics.

  本发明涉及使用A1腺苷受体拮抗剂来减少肺血管收缩并改善肺血液动力学。
• Pharmaceutical composition promoting defecation
  申请人：Yasuda Masahiro

  公开号：US20070054876A1

  公开（公告）日：2007-03-08

  The present invention provides a medicament having a gentle but strong defecation-promoting action without causing diarrhea. That is, it provides a defecation-promoting agent comprising a compound having an adenosine A 2 receptor antagonism, preferably an adenosine A 2b receptor antagonism, or a salt thereof.

  本发明提供了一种药物，具有温和但强效的促排便作用，而不会引起腹泻。也就是说，它提供了一种促排便剂，包括具有腺苷A2受体拮抗作用的化合物，优选为腺苷A2b受体拮抗作用的化合物或其盐。
• Compositions and methods for preventing restenosis following revascularization procedures
  申请人：Discovery Therapeutics, Inc.

  公开号：US20010009907A1

  公开（公告）日：2001-07-26

  In the present invention, a method is provided which reduces or prevents restenosis following revascularization procedures. It has now been found that selective stimulation of adenosine A 2A receptors can reduce or prevent such restenosis. This method may be achieved either by: (a) the administration of selective adenosine A 2A receptor agonists, (b) the administration of a selective adenosine A 1 antagonist in combination with either a selective adenosine A 2A receptor agonist or a non-selective adenosine agonist, or (c) the administration of a selective adenosine A 1 antagonist in order to block adenosine A 1 receptor activation by endogenously-released adenosine. The present invention is also directed to an improved surgical procedure that relies upon selective stimulation of adenosine A 2A receptors.

  本发明提供了一种方法，可减少或防止血管再通手术后的再狭窄。现已发现，选择性刺激腺苷 A 2A 受体可减少或预防此类再狭窄。这种方法可以通过以下方式实现(a) 给予选择性腺苷 A 2A 受体激动剂，(b) 使用选择性腺苷 A 1 拮抗剂与选择性腺苷 A 2A 受体激动剂或非选择性腺苷激动剂，或 (c) 使用选择性腺苷 A 1 拮抗剂，以阻断腺苷 A 1 受体被内源性释放的腺苷激活。本发明还涉及一种改进的外科手术方法，它依赖于选择性刺激腺苷 A 2A 受体。
• Methods and kits for the detection of endotoxi
  申请人：——

  公开号：US20020182641A1

  公开（公告）日：2002-12-05

  Methods for determining levels of endotoxin in a sample are provided. These methods are useful in the diagnosis of septicemia. Kits for the detection of endotoxin are also provided.

  提供了测定样本中内毒素水平的方法。这些方法可用于败血症的诊断。还提供了检测内毒素的试剂盒。
• Condensed purine derivatives
  申请人：KYOWA HAKKO KOGYO KABUSHIKI KAISHA

  公开号：EP0423805B1

  公开（公告）日：2000-08-23